Loading...
Odonate Therapeutics, Inc.
ODT•NASDAQ
HealthcareBiotechnology
$1.12
$-0.05(-4.27%)
Odonate Therapeutics, Inc. (ODT) Stock Overview
Explore Odonate Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ODTStats details for ODT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ODTAnalyst Recommendations details for ODT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
CEO
Mr. Kevin Tang
Employees
137
Headquarters
4747 Executive Dr Ste 510, San Diego, CALIFORNIA
Founded
2017